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Muscle pain may be part of many neuromuscular disorders including myopathies, peripheral neuropathies and lower motor 
neuron diseases. Although it has been reported also in mitochondrial diseases (MD), no extensive studies in this group of 
diseases have been performed so far. We reviewed clinical data from 1398 patients affected with mitochondrial diseases listed 
in the database of the “Nation-wide Italian Collaborative Network of Mitochondrial Diseases”, to assess muscle pain and 
its features. Muscle pain was present in 164 patients (11.7%). It was commonly observed in subjects with chronic progres-
sive external ophthalmoplegia (cPEO) and with primary myopathy without cPEO, but also—although less frequently—in 
multisystem phenotypes such as MELAS, MERFF, Kearns Sayre syndrome, NARP, MNGIE and Leigh syndrome. Patients 
mainly complain of diffuse exercise-related muscle pain, but focal/multifocal and at rest myalgia were often also reported. 
Muscle pain was more commonly detected in patients with mitochondrial DNA mutations (67.8%) than with nuclear DNA 
changes (32.2%). Only 34% of the patients showed a good response to drug therapy. Interestingly, patients with nuclear 
DNA mutations tend to have a better therapeutic response than patients with mtDNA mutations. Muscle pain is present in 
a significant number of patients with MD, being one of the most common symptoms. Although patients with a myopathic 
phenotype are more prone to develop muscle pain, this is also observed in patients with a multi system involvement, repre-
senting an important and disabling symptom having poor response to current therapy. 
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Mitochondria are a double membrane-bound organelles 
largely present in every tissue of human body, especially 
in those who require more energy as skeletal muscles 
and nervous tissue [1, 2]. Their functions are very vast, 
mainly supporting aerobic respiration and producing 
energy substrates such as ATP by oxidative phosphoryla-
tion (OXPHOS). They also contribute to various cellular 
metabolisms as β-oxidation, Krebs circle and lipid syn-
thesis [1, 2]. 
Mitochondrial diseases (MD) are caused by a deficiency 
of OXPHOS function, which is under control of both mito-
chondrial (mtDNA) and nuclear (nDNA) genomes [1–3]. 
Prevalence of nDNA and mtDNA mutations related to 
adult MD has been estimated around 1 of 4300 [4]. 
OXPHOS-affecting diseases have a wide spectrum of 
clinical manifestations ranging from complex multisys-
tem disorders to more easily identifiable mitochondrial 
syndromes or mild non-specific conditions characterized 
by fatigue and exercise intolerance [1–3]. 
Muscle pain can be part of many neuromuscular disor-
ders including myopathies, peripheral neuropathies and 
lower motor neuron diseases [5]. Although it has been 
reported also in mitochondrial patients, no extensive stud-
ies to quantify and clinically characterize muscle pain in 
MD have been performed so far [6–12]. 
Aim of the present study is to better investigate the symp-
tom “muscle pain” in a large cohort of patients affected with 
MD collected through the “Nation-wide Italian Collabora-




Patients and methods 
 
We retrospectively reviewed the clinical data of all the 
1398 patients present in the “Nation-wide Italian Col-
laborative Network of Mitochondrial Diseases” database 
updated at December 31st, 2016. 
The inclusion of patients in the database was approved 
by the Ethics Committee of each single center belonging 
to the network. We obtained the informed consent of all 
patients or their tutors in accordance with ethical standards 
of the 1964 Declaration of Helsinki. 
All involved centers have specific expertise in mito-
chondrial disorders and neuromuscular diseases. The clini-
cal section of our web-based database includes “yes or no” 
dichotomic items agreed by all centers in a preliminary 
consensus phase, which was specifically designed to define 
the clinical features known to be relevant in mitochondrial 
medicine, including muscle pain [13–15]. 
 
Patients were selected on the basis of the complaint, at 
least for the past 4 months, of muscle pain. After identify-
ing patients complaining of muscle pain, we designed a 
specific form to obtain more detailed informations. For 
every patient the following clinical data were collected: 
age, final diagnosis, distribution of pain (generalized or 
limited to one or more muscles) and its association with 
cramps/contractures, mode of presentation (at rest, exer-
cise-related or both), at rest serum creatine kinase (CK) 
and lactic acid levels, electromyography/electroneurogra-
phy (EMG/ENG) findings, histologic and histochemical 
studies and genetic results. The form was sent to the indi-
vidual centers that had recruited at least one patient with 
muscle pain. 
Assessment of active rheumatologic, infectious, meta-
bolic or endocrine disorders, myoglobinuria, fibromyalgia, 
restless leg syndrome, radiculo- or plexopathy, regular use 
of drugs known to trigger muscle pain (i.e., zidovudine, 
emetine, hydroxychloroquine, simvastatin, and pravastatin), 
alcohol abuse, electrolyte imbalance, and hypereosinophilia 
was conducted. Patients affected with these conditions and 
those having neuropathic pain (published in Ref. [14]) were 
excluded from the study. 
Prevalence, distribution, and mode of presentation of 
muscle pain and related phenotypes and genotypes were 
analyzed; the correlation with EMG/ENG findings, serum 
CK and lactate values, muscle biopsy and clinical response 
to therapy was also investigated. 
Comparisons of proportions have been performed by Chi-
squared test, two-tailed Fischer’s exact test and t student test. 
A P value <0.05 was considered as significant. Data analysis 






Among the 1398 patients included on database, 164 (11.7%) 
complained of muscle pain. 
Figure 1 analyses the frequency of muscle pain within 
each main phenotype and reveals that muscle pain is more 
commonly reported by patients with primary mitochondrial 
myopathy without chronic progressive external ophthal-
moplegia (PMM) (44.6% of the total PMM subjects) and 
by chronic progressive external ophthalmoplegia (cPEO) 
patients (11% of the total cPEO subjects). However, it is 
also a common symptom in multi system phenotypes such 
as mitochondrial encephalopathy, lactic acidosis, and stroke-
like episodes (MELAS) (6.1% of the total MELAS subjects), 
myoclonic epilepsy with ragged red fibers (MERRF) (11.3% 
of the total MELAS subjects) and mitochondrial neurogas-
trointestinal encephalopathy syndrome (MNGIE) (17.7% of 




Fig. 1 Muscle pain along differ-
ent mitochondrial phenotypes in 
the cohort from Italian National 
Database. Frequency expressed 
in percentage of patients. 
PMM primary mitochondrial 
myopathy without cPEO, cPEO 
chronic progressive external 
ophthalmoplegia, MELAS 
mitochondrial myopathy, 
encephalopathy, lactic acidosis, 
and stroke, MERRF myoclonic 
epilepsy with ragged red fibers, 
NARP neuropathy, ataxia, and 
retinitis pigmentosa, Leigh 
Leigh syndrome, MNGIE mito-
chondrial neurogastrointestinal 
encephalopathy, KSS Kearns– 
Sayre syndrome. In vertical axis 






We could collect full information in 132 of the 164 subjects. 
Median age at the diagnosis of MD was 58.2 ± 14.4 years, 
range 4–85. Seventy-four subjects are males (56%) and 58 
(44%) females. A childhood disease was reported in 3.7% 
of cases. 
Muscle pain was reported by all the patients, in 59 
(44.7%) in association with muscle cramps/contractures. 
Symptoms were present from a minimum of 4 months to a 
maximum of 18 years; they were widespread in 74 patients 




















Fig. 2 a Pattern of distribution of muscle pain in our cohort. In blue 
are represented patients having widespread muscle pain while in red 
patients complaining of focal/multifocal muscle pain. Purple, light 
blue, and orange bars represent main segments involved (lower limbs, 
upper limbs and trunk, respectively) in the subgroup of patients 
 
mainly at lower limbs (40.2%) than upper limbs or trunk 
(12.9% and 2.2%, respectively) (Fig. 2a). 
In 53 patients (40.2%; 32.4% of widespread and 50% of 
focal/multifocal patients) muscle pain was exercise-related, 
in 25 (18.9%; 25.7% of widespread and 10.3% of focal/mul-
tifocal patients) only at rest, and in the remaining 54 (40.9%; 
41.9% of widespread and 39.7% of focal/multifocal patients) 
either at rest or after exertion (Fig. 2b). 
Few patients had some conditions that might have influ-
enced muscle pain in their past medical history as diabetes 
mellitus (22%), hypothyroidism (9.1%), Hashimoto thyroidi-




















having focal/multifocal muscle pain. In vertical axis percentage of 
patients. b Mode of presentation (E exercise-related, R/E at rest and 
exercise-related, R at rest) of muscle pain in our cohort. In vertical 




all these conditions were well treated and under control 
when the patients have been evaluated. 
Among the 132 patients selected for this study, PMM 
(34.8%), cPEO (32.6%), MELAS (6.7%), and MERFF 
(6.7%) were the more represented phenotypes while other 
non-specific phenotypes account for 11.1% of the patients 
(Fig. 3). 
Although diagnosis is defined in all the patients by clini-
cal, biochemical and/or morphological findings, a conclusive 
molecular diagnosis was available in 87 subjects out of 132 
(65.9%); 59 (67.8%) patients harbored a mtDNA mutation 
(22% a single deletion and 78% a point mutation). Only one 
out of these patients had a mutation in the MT-CYB gene 
[m.15800C-T (p.Glu352*)]. Mutations in nDNA genes were 
detected in 28 patients (32.2%). More frequent mutated 
genes were POLG (39.3%), TWNK (17.8%), TYMP (10.7%) 
and OPA1 (7.1%). 
The median age at the diagnosis was 43.79 ± 14.06 in 
the genetically defined patients and 53.72 ± 16.42 in patients 
with still not defined genetic diagnosis (p< 0.001). No sig-
nificant statistical differences in all the considered character-
istics of pain were found between the two groups. 
Nerve conduction studies were normal except a mild 
sensory-motor neuropathy observed in five patients (3.8%). 
Electromyography revealed myopathic changes in 42.6%, 
neurogenic changes in 20.8%, a mixed pattern in 24.8%, 






















Fig. 3 Distribution of muscle pain within the main mitochondrial 
phenotypes in our cohort. PMM primary mitochondrial myopathy 
without cPEO, cPEO chronic progressive external ophthalmoplegia, 
MELAS mitochondrial myopathy, encephalopathy, lactic acidosis, and 
stroke, MERRF myoclonic epilepsy with ragged red fibers, MNGIE 
mitochondrial neurogastrointestinal encephalopathy, NARP neuropa-
thy, ataxia, and retinitis pigmentosa, Leigh Leigh syndrome 
Serum CK level, measured in all the patients, was normal 
in 47% of them, while it was elevated up to two times beyond 
the normal limit in 53%. 
Blood lactate level was available in 92 (69.7%) patients: 
58 (63%) had normal level (below 2.2 mmol/L), 18 (19.6%) 
a level between 2.2 and 3.0 mmol/L, 11 (12%) between 3.0 
and 4.0 mmol/L and 5 (5.4%) over 4.0 mmol/L. 
Muscle biopsy was performed on 127 patients (96.2%) 
and showed pathological signs in 115 (90.5%). Some of 
them were non-specific signs of muscle damage, such as 
poly-dimensionalism of the fibers (47.7%) or centralization 
of nuclei (40.9%). More specific signs of mitochondrial dys-
function were accumulation of lipids (26.5%), ragged red 
fibers (61.4%), COX negative fibers (78.2%) and subsar-
colemmal rims (48.5%). 
Statistical analysis did not reveal any significant corre-
lation between muscle pain appearance/characteristics and 
genotype, EMG/ENG findings, serum CK and lactate values 
and histological data. There was no statistically significant 
difference in EMG–ENG findings between patients with or 
without muscle cramps/contractures. 
 
 
Management of muscle pain and response 
to therapy 
 
The most used drugs in the treatment of muscle pain were 
nonsteroidal anti-inflammatory drugs (NSAIDs) and modu-
lators of neuropathic pain such as pregabalin, gabapentin, 
SSRI, SNRI (i.e., venlafaxine) and tricyclic antidepressant 
(i.e., amitriptyline). All the patients received at least one 
medication for treating pain and they were considered non-
responders if response to multiple drugs (at least three) was 
unsatisfactory. Only 45 subjects (34%) showed a satisfactory 
improvement in painful symptoms after drug administration; 
27 were male and 18 were female (no statistically difference 
was detected). 
In this subgroup, main used drugs were NSAIDs such as 
ASA or paracetamol, pregabalin and gabapentin. 
We analyzed the characteristics of the subgroup who 
showed a clinical response to treatment. 
These patients presented a similar muscle pain distribu-
tion to those who did not respond to therapy: 24 (53.3%) 
complained about diffuse muscle pain and 21 (46.7%) of 
focal/multifocal myalgia. 
Responders/non-responders comparison of EMG data, 
available in 38 cases, showed a similar prevalence of myo-
pathic pattern (44.7% vs. 42.6%) with a higher prevalence 
of neurogenic signs in responders (34.2% vs. 20.8%) and a 
high prevalence of mixed pattern in non-responders (7.9% 
vs. 24.8%) but with no statistical significance. Normal EMG 




Among the 87 patients with molecular diagnosis, 35 
were responders and 52 were non-responders. In responder 
subjects the frequency of mtDNA mutations was 62.9% (22 
subjects) and of nDNA mutations 37.1% (13 subjects). In 
non-responders the frequency of mtDNA mutations was 
84.6% (44 subjects) and of nDNA mutations 15.4% (8 sub-
jects). The analysis of the difference in frequency of mtDNA 
vs. nDNA mutations between responders and non-respond-
ers showed an increased frequency of nDNA mutations in 






The relation between muscle pain and mitochondrial abnor-
malities is already known, although the exact underlying 
mechanisms are poorly understood. 
Twenty per cent out of 240 patients submitted to muscle 
biopsy for muscle pain have been reported to have mitochon-
drial abnormalities at the muscle biopsy, including COX 
negative and ragged red fibers or subsarcolemmal mitochon-
drial accumulation [16]. 
Several studies showed mitochondrial damage as one 
of the mechanisms by which statins (a well-known class 
of drugs causing muscle pain) can cause myotoxicity thus 
indirectly confirming the role of mitochondrial dysfunction 
in causing muscle pain [17–19]. 
The best characterized muscle pain MD syndrome is 
due to cytochrome-b mutations, the only mtDNA-encoded 
subunit of complex III, that commonly cause a myopathy 
characterized by exercise intolerance, muscle pain and myo-
globinuria [6]. 
At rest or exercise-related muscle pain was also described, 
usually as isolated case reports, in some patients harboring 
mitochondrial tRNA gene mutations, including MT-TL1, 
MT-TS1 and MT-TK [7–12]. 
However, systematic studies in this field are missing 
in the literature and muscle pain clinical characterization 
remains poorly investigated. 
As a first significant finding, our study shows that muscle 
pain appears to be an important clinical feature of MD, being 
present in almost 12% of cases, thus representing a daily 
clinical and therapeutic problem. 
Muscle pain characteristics are heterogeneous. It (1) is 
more generalized than focal/multifocal, (2) involves lower 
limbs more than upper limbs, and (3) manifests more fre-
quently after exercise than only at rest. However, the global 
number of subjects complaining of rest pain, either associ-
ated or not to exercise-induced muscle pain, is about 60% 
and this is an interesting evidence to keep in mind in a clini-
cal setting. 
A second important finding coming from our analysis is 
that muscle pain is a frequent complain not only in patients 
with myopathic pictures but also in subjects having more 
complex phenotypes such as MELAS, MERRF, neuropathy, 
ataxia, and retinitis pigmentosa (NARP), MNGIE, Kearns 
Sayre syndrome (KSS) and Leigh syndrome. 
Although these complex phenotypes account for a minor-
ity of the cases in our database, the evidence that a part of 
the affected subjects complains of muscle pain as an impor-
tant and disabling symptom should be stigmatized. 
Interestingly, only 11% out of cPEO patients collected 
in our database complained of muscle pain, even though 




Fig. 4 Relation between geno-
type and response to treatment. 
The analysis of the difference in 
frequency of mtDNA vs. nDNA 
mutations between responders 
and non-responders showed an 
increased frequency of nDNA 
mutations in responder patients 
with statistical significance 
with p< 0.01. In horizontal axis 













EMG, serum CK, and lactate remain of scarce use-
fulness in characterizing MD patients with muscle pain 
because of variable EMG patterns and serum CK/lactate 
values. We can stress that most of the patients presents 
with a myopathic or mixed neurogenic/myopathic EMG 
pattern and serum CK values variably above normal val-
ues. Only in 37% of the patients, increased values of serum 
lactate were detected. 
No significant correlation between muscle biopsy find-
ings and muscle pain which can help in better characterize 
and diagnose it was found. At the same way, no significant 
correlation between genotype (mtDNA mutations vs. nDNA 
mutations) and muscle pain was found, although patients 
with mtDNA mutations more frequently complained of mus-
cle pain than nDNA-mutated patients (67.8% vs. 32.2%). 
A third interesting observation deriving from this study is 
that pharmacological control of muscle pain in these patients 
is largely unsatisfactory, being reached in only 34% of them 
by using a variety of analgesic and modulating drugs. 
Although an assessment of quality of life was out of 
the scope of this study, it is self-evident that, as in other 
settings, quality of life of our non-responder patients is 
largely compromised by the presence of chronic pain and 
better and more specific therapies appear necessary. 
An additional interesting observation, although of elu-
sive significance, is the higher prevalence of responder 
patients among the nDNA-mutated subjects respect to 
mtDNA-mutated ones, which is a statistically significant 
difference suggesting a possible role of genotype in influ-
encing the response to therapy. 
Certainly, our study has some limitations. First of all 
its retrospective design, which did not allowed to obtain 
assessment scales such as the visual analog scale (VAS 
score) or depression scale findings. Therefore, for exam-
ple, we cannot entirely exclude that, in a number of 
patients, the origin of pain could be not strictly metabolic 
related, since, in the course of chronic diseases as MD, 
overlapping conditions including fibromyalgia, depression 
and psychosomatic illness can appear making it dificult to 
distinguish between pain due primarily to mitochondrial 
deficiency and that due to associated comorbidities. 
However, independently from the cause of muscle pain, 
our study represents the first picture of the “real world” as 
physicians usually observe in clinical practice. 
Our findings indicate that muscle pain is frequent in 
patients with MD and it is a management and therapeutic 
problem. Further research should be guaranteed to better 
understand pathogenesis and improve the current unsatis-
factory treatment. 
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